Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Psychiatric Quarterly
Published in: Psychiatric Quarterly 4/2017

01-12-2017 | Original Paper

Reliability and Validity of the Short Version of Udvalg for Kliniske Undersogelser in Antipsychotic Treatment

Authors: Kun-Po Chen, For-Wey Lung

Published in: Psychiatric Quarterly | Issue 4/2017

Login to get access

Abstract

The aim of this study was to develop a reliable and valid short version of the Udvalg for Kliniske Undersogelser (UKU) to efficiently evaluate the side effects of antipsychotics in patients with schizophrenia. This multi-site study included 10 hospitals, which included 331 inpatients and outpatients diagnosed with schizophrenia. UKU, Clinical Global Impression-Severity (CGI-S), Personal and Social Performance (PSP) and dosage of paliperidone were collected. The predictive validity of the UKU-short version, as well as that of the CGI-S, PSP and paliperidone dosages, was analyzed using structural equation modeling (SEM), latent growth models (LGM), and confirmatory factor analysis to test its content and construct validity. The UKU-short included nine-items of sedation, reduced sleep, rigidity, tremor, akathisia, headache, reduced salivation, constipation and orthostatic dizziness, and has good construct and content validity over time. Confirmatory factor analysis showed good construct validity, with the psychic, neurological and autonomic side effect dimensions having correlations between 0.60 and 0.71. The predictive validity of the short-version UKU for psychiatric symptoms (CGI-S), quality of life (PSP) and dosage showed that the effects of drug dosage were negligible, and only neurological side effects were associated with psychiatric symptoms and quality of life. The UKU-short showed good content, construct and predictive validity. It is a more time-efficient instrument than the original UKU. This study only included patients treated with paliperidone, larger scale studies is needed to validate the UKU-short in detection of side effects in routine clinical practice to prevent non-adherence in patients with schizophrenia.
Literature
1.
Donohoe G, Owens N, O'Donnell C et al. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry 2001;16:293-8.CrossRefPubMed
2.
Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv. 2003;54:665-777.CrossRefPubMed
3.
Velligan DI, Weiden PJ, Sajatovic M et al. Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70 Suppl 4:1-46.PubMed
4.
Kane JM. Dosage and route of administration of neuroleptic drugs during different phases of schizophrenia illness. In: Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin: Springer; 1994.
5.
Lader M, Lewander T. The neuroleptic-induced deficit syndrome. Acta Psychiatr Scand. 1994;89 (Suppl 380):1-85
6.
Day JC, Wood G, Dewy M, Bentall RP. A self-rating scale for measuring neuroleptic side effects: Validation in a group of schizophrenic patients. Br J Psychiatry 1995;166:650-3CrossRefPubMed
7.
Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012;379:2063-71CrossRefPubMed
8.
Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005;20:15-27.CrossRefPubMed
9.
Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology 2000;148:3-15.CrossRefPubMed
10.
Piparva KG, Buch JG, Chandrani KV. Analysis of adverse drug reactions of atypical antipsychotic drugs in psychiatry OPD. Indian J Psychol Med. 2011;33:153-7.CrossRefPubMedPubMedCentral
11.
Levine M, Ruha AM. Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management. CNS Drugs 2012;26:601-11.CrossRefPubMed
12.
Minns AB, Clark RF. Toxicology and overdose of atypical antipsychotics. J Emerg Med. 2012;43:906-13.CrossRefPubMed
13.
14.
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Legen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic treated patients. Acta Psychiatrica Scand. 1987;76:1-100.CrossRef
15.
Lambert TJR, Cock N, Alcock SJ, Kelly DL, Conley RR. Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Hum Psychopharmacol Clin Exp. 2003;18:405-11.CrossRef
16.
Potkin SG, Thyrum PT, Alva G, Bera R, Yeh C, Arvanitis LA. The safety and pharmacokinetics of quetiapine with coadministered with haloperidol, risperidone, or thioridazine. J Psychopharmacol. 2002;22:121-30.CrossRef
17.
Chen YL, Cheng TS, Lung FW. Prolactin levels in olanzapine treatment correlate with positive symptoms of schizophrenia: results from an open-label, flexible-dose study. Prim Care Companion J Clin Psychiatry 2009;11:16-20.CrossRefPubMedPubMedCentral
18.
Fleischhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatrica Scand. 1994;89:11-5.
19.
Wang CS, Kao WT, Chen CD, Tung YP, Lung FW. Priapism associated with typical and atypical antipsychotic medications. Int Clin Psychopharmacol. 2006;21:245-8.CrossRefPubMed
20.
Lee HH, Chu YH, Ruan FF, Tzeng DS, Lung FW. Confirmatory factor analysis of the Sexual Desire Inventory for schizophrenia patients. Taiwanese Journal of Psychiatry 2007;21:176-83.
21.
22.
23.
Ong J, Wong W, Lee A, Holroyd E, Huang SY. Sexual activity and adolescent health risk behaviours amongst high school students in three ethnic Chinese urban populations. J Clin Nurs. 2013;22:3270-9.CrossRefPubMed
24.
Tsai JK, Lin WK, Lung FW. Social interaction and drug attitude effectiveness in patients with schizophrenia. Psychiatr Q. 2011;82:343-51.CrossRefPubMed
25.
Guy W. Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Revised. NIMH publication DHEW publ NO (Adm). Bethesda MD: National Institute of Mental Health; 1976.
26.
27.
Anastasi A, Urbina S. Psychological testing, 7th ed. New York: Prentice Hall; 1997.
28.
Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res. 1997;6:21-6.CrossRefPubMed
29.
Fujimaki K, Takahashi T, Morinobu S. Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia. PLoS ONE 2012;7:e37087.CrossRefPubMedPubMedCentral
30.
Ghisletta P, Lindenberger U. Static and dynamic longitudinal structural analyses of cognitive changes in old age. Gerontology 2004;50:12-6.CrossRefPubMed
31.
32.
Chugh PK, Rehan HS, Unni KES, Sah RK. Predictive value of symptoms for quality of life in first-episode schizophrenia. Nord J Psychiatry 2013;67:153-8.CrossRefPubMed
33.
Yang MC, Lung FW. Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide25-35, N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death. Psychopharmacology 2011;217:397–410.CrossRefPubMed
Metadata
Title
Reliability and Validity of the Short Version of Udvalg for Kliniske Undersogelser in Antipsychotic Treatment
Authors
Kun-Po Chen
For-Wey Lung
Publication date
01-12-2017
Publisher
Springer US
Published in
Psychiatric Quarterly / Issue 4/2017
Print ISSN: 0033-2720
Electronic ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-017-9494-y

Other articles of this Issue 4/2017

Psychiatric Quarterly 4/2017 Go to the issue

Review Article

Reconsidering Emotion Dysregulation

Original Paper

The Working Alliance in Psychiatric Care: Agreement Communication and Trust in Action

Review Article

Correlates of the Third Victim Phenomenon

Original Paper

The Patient-Psychiatrist Relationship on the Axis of the Other and the Same

Original Paper

Predictors and Prevalence of Recovery and Remission for Consumers Discharged from Mental Hospitals in a Chinese Society

Original Paper

Total Tau and Phosphorylated Tau Protein Serum Levels in Patients with Schizophrenia Compared with Controls